ArticleMetabolomics : Official journal of the Metabolomic Society2026
Evaluation of metabolite biomarker candidates in detecting HCC in patients with liver cirrhosis.
Article in Metabolomics : Official journal of the Metabolomic Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionHepatocellular carcinoma (HCC), the most prevalent form of liver cancer, ranks as the third leading cause of mortality globally. Patients diagnosed with HCC exhibit a dismal prognosis, mostly due to the emergence of symptoms in the advanced stages of the disease. Moreover, conventional biomarkers demonstrate insufficient efficacy in the early detection of HCC, hence highlighting the need for the identification of novel and more effective biomarkers. This study aims to evaluate a selected panel of serum biomarker candidates for the detection of HCC in patients with liver cirrhosis (CIRR). This is accomplished by targeted quantitation of the candidates using a triple quadrupole mass spectrometer.
methodsSerum samples from 50 HCC cases (27 Stage I HCC), 50 patients with CIRR, and 25 healthy controls were analyzed using ultra-high-performance liquid chromatography-TSQ Altis Plus triple quadrupole mass spectrometry (UHPLC-MS/MS) by multiple reaction monitoring (MRM). Absolute quantification of 13 endogenous metabolites selected from previous studies was performed using the surrogate matrix approach by creating calibration curves for each metabolite. Statistical analyses included univariate testing with false discovery rate (FDR) correction, multivariable logistic regression adjusted for clinical covariates, and receiver operating characteristic (ROC) curves.
resultsSix metabolites primarily involving amino acid and bile acid metabolism were significantly altered in HCC vs. CIRR, with four of these also significant in Stage I HCC vs. CIRR. While AFP alone achieved AUCs of 0.773 ± 0.106 in HCC vs. CIRR and 0.804 ± 0.093 in Stage I HCC vs. CIRR. The combination of AFP with a six-metabolite panel improved discrimination (AUCs 0.870 ± 0.083 and 0.877 ± 0.059, respectively). Among the six metabolites, ornithine and proline remained associated with HCC after adjusting for confounding factors such as age, sex, BMI, MELD score, and HCV status.
conclusionTargeted metabolomics reveals reproducible metabolic alterations in HCC, including early-stage disease; however, substantial overlap with cirrhosis limits their independent diagnostic utility. Integration with AFP provides modest improvement, supporting a complementary multi-marker approach for HCC detection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.